AmStem Corporation announced positive early results from its preliminary consumer study of SteMixx™. Full study results will be available at the end of this month. AmStem has engaged a labeling consultant for their flagship SteMixx™ product to make it available for retail consumer use as soon as possible in the U.S. AmStem has finalized its submission to an independent Institutional Review Board (IRB) to begin the first clinical trial of SteMixx in the United States.

Read the full story here